Describe the epidemiology and prevention of pulmonary tuberculosis. Add a note on National Tuberculosis Elimination Program (NTEP): Objectives, strategies and newer initiatives.

Reading File
Finding Sources
Finding Sources
Searching the Web

National Tuberculosis Elimination Program NTEP India objectives strategies newer initiatives 2025

Reading File
Finding Sources
Finding Sources
Reading Web Page

https://en.wikipedia.org/wiki/National_TB_Elimination_Progra…

Reading File
Reading Web Page

https://www.pib.gov.in/PressReleasePage.aspx?PRID=2244661&re…

Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
I now have comprehensive data. Let me compile the full answer.

Epidemiology and Prevention of Pulmonary Tuberculosis

A. EPIDEMIOLOGY

1. Global Burden

Infection with Mycobacterium tuberculosis is prevalent throughout the world. An estimated 1.7 billion people (one-fourth of the world population) are infected with M. tuberculosis, though distribution is heterogeneous. In 2018, there were an estimated 10 million new TB cases, of which only 7.0 million were reported to national public health authorities - leaving approximately 3 million unaccounted for. In the same year, 1.2 million deaths were attributed to TB, with a case fatality rate of approximately 15%.
About 86% of cases are concentrated in three WHO regions: Southeast Asia (44%), Africa (24%), and the Western Pacific (18%). Most high-income countries have an incidence of less than 10 new cases per 100,000 population. In 2018, the UN General Assembly held its first-ever high-level meeting on TB and heads of state committed to ending TB by 2030 under the WHO End TB Strategy.
  • Murray & Nadel's Textbook of Respiratory Medicine, p. 1161

2. India-Specific Burden

India carries the highest TB burden in the world in absolute numbers, accounting for 26% of estimated global incident TB cases in 2019.
Table: Burden of Tuberculosis in India (2019) - Population 1,366 million
ParameterNumber (thousands)Rate (per 100,000)
Total incidence2,640 (1,800-3,630)193 (132-266)
HIV+TB incidence71 (49-98)5.2 (3.6-7.2)
MDR/RR-TB incidence124 (73-189)9.1 (5.3-14)
Mortality (HIV-negative TB)436 (404-469)32 (30-34)
Mortality (HIV-positive TB)9.5 (6-14)0.69 (0.44-1)
  • New TB cases with MDR/RR-TB: 2.8%
  • Previously treated cases with MDR/RR-TB: 14%
  • TB treatment coverage: 82%
  • Case fatality ratio: 17%
  • Of notified cases, 78% were pulmonary TB
  • Park's Textbook of Preventive and Social Medicine, p. 210

3. Age and Sex Distribution

  • TB predominantly affects the 15-30 year age group (adolescents and young adults), indicating ongoing active transmission.
  • In southern states (Kerala, Karnataka, Tamil Nadu, Andhra Pradesh), there is a shift toward elderly predominance (50+ years).
  • Globally, males are affected more than females, with higher rates in productive age groups.

4. Causative Agent (Agent Factors)

  • Mycobacterium tuberculosis is the primary causative organism - an obligate aerobe, non-spore-forming, non-motile, acid-fast bacillus.
  • M. tuberculosis has 7 major phylogenetic lineages with geographic structure: Indo-Oceanic (L1), East-Asian (L2), Indian/East-African (L3), Euro-American (L4), West-African 1 & 2 (L5, L6), and Ethiopian (L7). Different lineages are associated with differing pathogenicity.
  • The source of infection is humans with active pulmonary tuberculosis who release mycobacteria through sputum. Oropharyngeal and intestinal TB may arise from contaminated milk (M. bovis).
  • Robbins Pathologic Basis of Disease; Murray & Nadel, p. 1161

5. Host Factors (Risk Factors for Disease)

Infection progresses to active disease in approximately 5-10% of immunocompetent individuals. Risk factors include:
CategorySpecific Risk Factors
ImmunosuppressionHIV (20-30x increased risk), TNF-alpha inhibitors, corticosteroids, organ transplant
NutritionalMalnutrition, underweight, Vitamin D deficiency
Medical conditionsDiabetes mellitus, silicosis, CRF/dialysis, cancer
Social/behavioralOvercrowding, poverty, alcohol/tobacco use, incarceration
OccupationalHealthcare workers, miners
BiologicalAge <5 years, adolescents, elderly; male sex
Prior TBHistory of inadequately treated TB; fibrotic lesions on CXR
People living with HIV are 20 to 30 times more likely to develop TB than those without HIV, making HIV the single most important determinant of TB epidemiology.
  • Murray & Nadel; Park's Textbook, p. 215

6. Environmental Factors

  • Overcrowding is the most important environmental factor - facilitates droplet nuclei transmission.
  • Poor ventilation and inadequate sunlight in dwellings.
  • Urban slums and congregate settings (prisons, hostels, shelters).
  • Industrial and occupational exposure (silica dust).

7. Mode of Transmission

  • Airborne transmission via droplet nuclei (1-5 microns diameter) containing viable bacilli, produced by coughing, sneezing, or talking by infectious cases.
  • A single smear-positive untreated case can infect 10-15 persons per year.
  • Droplet nuclei remain suspended in air for hours and travel long distances.

8. Annual Risk of Infection (ARI)

The ARI represents the probability of a person being newly infected (or re-infected) in a given community. In developing countries, every 1% ARI corresponds to approximately 50 new smear-positive pulmonary TB cases per year per 100,000 population. Also known as the "tuberculin conversion index," it is considered one of the best epidemiological indicators of the TB problem and its trend.
  • Park's Textbook, p. 213

B. PREVENTION OF TUBERCULOSIS

Prevention and control rest on two fundamental pillars:
  1. Curative component - Case finding and treatment (the most powerful weapon)
  2. Preventive component - BCG vaccination

1. Case-Finding

a. Passive case-finding: Over 60% of pulmonary TB patients seek medical advice on their own because of chest symptoms (persistent cough, fever). This is the most productive group for case detection.
b. Intensified TB Case-Finding (ICF): A provider-initiated strategy targeting clinically, socially, and occupationally vulnerable populations:
  • Community screening (mobile/fixed facilities, door-to-door)
  • Institutional screening (health-care facilities, prisons, homeless shelters, refugee camps)
  • Screening strategies use symptom screening, chest X-ray, molecular tests (Xpert MTB/RIF)

2. Treatment (Chemotherapy as Prevention)

Prompt and effective treatment of active cases breaks the chain of transmission and is the most powerful tool in tuberculosis control. Cure of a smear-positive case removes the most infectious reservoir.
Tuberculosis Preventive Treatment (TPT): Targeted preventive chemotherapy for:
  • Household contacts of bacteriologically confirmed cases (especially children <5 years)
  • People living with HIV (PLHIV)
  • High-risk/vulnerable populations
Regimens include 6H (6 months isoniazid), 3HP (3 months weekly isoniazid + rifapentine), or 1 month daily isoniazid + rifapentine (1HP).

3. BCG Vaccination

BCG (Bacille Calmette-Guerin) - the only licensed TB vaccine:
  • Efficacy: Studies have shown 80% effectiveness over 20 years against severe childhood TB and tuberculous meningitis. However, BCG efficacy against adult pulmonary TB varies widely in different trials (0-80%).
  • Indian Policy: BCG is given at birth (for institutional deliveries) or at 6 weeks simultaneously with DPT and polio. Given intradermally, 0.1 mg in 0.1 ml (0.05 ml for neonates) just above the insertion of the left deltoid muscle.
  • Reaction: 2-3 weeks post-injection a papule develops, reaching 4-8 mm by 5 weeks, then subsides leaving a permanent scar 4-8 mm in diameter. The individual becomes Mantoux-positive after 8-14 weeks.
  • Complications: Prolonged ulceration (1-10%), suppurative lymphadenitis, osteomyelitis, disseminated BCG infection (<1 per million).
  • Park's Textbook, pp. 231-232

4. Infection Control Measures

  • Administrative controls: Early identification and isolation of infectious cases, respiratory hygiene (cough etiquette), rapid initiation of treatment.
  • Environmental controls: Natural or mechanical ventilation, UV germicidal irradiation (UVGI) in health facilities.
  • Personal protective equipment: N95 respirators for healthcare workers in high-risk settings.
  • AIRBORNE INFECTION CONTROL (AIC) under NTEP - a specific component addressing facility-based transmission.

5. Addressing Social Determinants

  • Reduction of poverty, malnutrition, overcrowding, and indoor air pollution.
  • Multisectoral response involving ministries of housing, social welfare, nutrition.
  • Nutritional supplementation for TB patients.

C. NOTE ON NTEP - National Tuberculosis Elimination Program

Historical Evolution

ProgramPeriodFocus
National Tuberculosis Programme (NTP)1962First TB programme; used BCG + drugs
Revised NTP (RNTCP)1992/97 nationwideDOTS-based strategy
RNTCP → NTEP2020Elimination goal; renamed to reflect ambition
In 2020, the Government of India renamed the RNTCP to the National Tuberculosis Elimination Programme (NTEP), reflecting India's goal to eliminate tuberculosis by 2025 - five years ahead of the WHO global target of 2030.
NTEP functions as a flagship component of the National Health Mission (NHM) and provides technical and managerial leadership to anti-tuberculosis activities across the country, providing free-of-cost quality TB diagnosis and treatment.

Objectives of NTEP

  1. To achieve TB elimination in India by 2025 (defined as <1 case per million population)
  2. Reduce TB incidence and mortality by 90% and 95% respectively by 2025 (compared to 2015 baseline)
  3. Ensure zero TB-affected families face catastrophic costs
  4. Universal access to quality TB care for all patients

National Strategic Plan (NSP) 2017-2025 - The Four Pillars

The NSP is built on four strategic pillars:
PillarCore Actions
DETECTEarly diagnosis through quality testing; proactive community outreach for missing cases; CB-NAAT/Xpert MTB/RIF; Line Probe Assays; Universal Drug Sensitivity Testing (UDST)
TREATPrompt treatment with quality-assured drugs; drug-resistant TB management; daily regimens (shift from intermittent to daily dosing)
PREVENTBCG vaccination; TB Preventive Treatment (TPT); airborne infection control; contact tracing
BUILDStrengthening health systems; IT infrastructure (Nikshay); accountability; private sector engagement; multisectoral response

Key Strategies

  1. DOTS (Directly Observed Treatment Short-course): Core of RNTCP/NTEP. Direct observation of drug intake ensures treatment completion.
  2. Universal Drug Susceptibility Testing (UDST): All newly diagnosed TB patients are tested for drug resistance upfront to guide treatment.
  3. Daily drug regimens: Shift from thrice-weekly to daily drug regimens to improve outcomes and reduce resistance.
  4. Private Sector Engagement: Mandatory notification of TB by private practitioners; Nikshay platform for seamless notification.
  5. Decentralization of services: TB Units at sub-district level; decentralized diagnosis and treatment.
  6. DR-TB management: Expansion of DRTB centers; shorter MDR-TB regimens; BPaLM regimen (Bedaquiline, Pretomanid, Linezolid, Moxifloxacin).

Newer Initiatives under NTEP

1. Nikshay - Web-Based Case Monitoring (2012)

A national web-based reporting and patient tracking platform capturing individual patient data from the remotest health institutions. Enables real-time monitoring of case notifications, treatment outcomes, and program performance. Used for TB case notification by both public and private providers.

2. Nikshay Poshan Yojana (2018)

Launched in 2018 to provide nutritional support to TB patients. TB patients receive Rs. 500/month directly via Direct Benefit Transfer (DBT) for the duration of their treatment, to counteract the adverse effects of anti-TB drugs and nutritional deficiencies that worsen outcomes.

3. Ni-kshay Mitra Programme (2022)

A community engagement initiative launched as part of PM TB Mukt Bharat Abhiyaan. Ni-kshay Mitras (volunteer "friends of TB patients") - individuals, corporates, NGOs, elected representatives - provide additional nutritional, diagnostic, and vocational support to TB patients. Links with Corporate Social Responsibility (CSR) funds.

4. Pradhan Mantri TB Mukt Bharat Abhiyaan (September 9, 2022)

A Jan Andolan (people's movement) launched by the Prime Minister to accelerate TB elimination. Its objectives are:
  • Provide additional support to TB patients to improve treatment outcomes
  • Augment community involvement
  • Leverage CSR funding and volunteer networks
  • Whole-of-society and whole-of-government approach

5. 100-Day TB Mukt Bharat Abhiyan (December 2024)

One of India's most intensive TB elimination drives, launched on 7 December 2024 in 347 high-priority districts across 33 States/UTs. Key features:
  • Vulnerability mapping and systematic screening of high-risk populations
  • Active involvement of 30,000+ elected representatives and 24 line ministries
  • Strategies later expanded nationwide to all districts

6. CB-NAAT / Xpert MTB/RIF Expansion

Cartridge-Based Nucleic Acid Amplification Test (CB-NAAT) provides accurate, rapid TB diagnosis AND rifampicin resistance detection in 90 minutes from unprocessed sputum. Massively expanded under NTEP for:
  • Children, PLHIV, Extra-pulmonary TB, smear-negative TB
  • Universal drug sensitivity testing

7. Line Probe Assay (LPA)

Rapid molecular test for simultaneous detection of M. tuberculosis and resistance to:
  • First-line LPA: Rifampicin (rpoB) and Isoniazid (katG, inhA)
  • Second-line LPA: Fluoroquinolones (gyrA, gyrB) and injectable drugs (rrs, eis)

8. Bedaquiline and New Drug Regimens

Introduction of Bedaquiline (BDQ) and Delamanid for MDR-TB treatment under conditional access programs, leading to significantly improved outcomes in drug-resistant TB.

9. Whole-of-Government & Multisectoral Response

Inclusion of 24 line ministries (housing, food, labor, education) for addressing social determinants. High-level commitment with the PM's personal involvement signals a TB-Free India as a national mission.

10. Airborne Infection Control

Specific NTEP guidelines for infection control in health facilities - administrative, environmental, and personal protection measures to prevent nosocomial and occupational TB transmission.

Summary of NTEP's Structure

NTEP
├── Central TB Division (CTD) - Ministry of Health & Family Welfare
├── State TB Cell (STC) - State level
├── District TB Centre (DTC) - District level
│   └── TB Unit (TU) - Sub-district supervisory unit
│       └── DOT Centre / Designated Microscopy Centre (DMC)
└── DRTB Centres - for MDR/XDR-TB

Key References:

Create a summary document on TB epidemiology and NTEP strategies

Asking for Preferences
Reading File
Reading File
Reading File
Running Command

mkdir -p /home/daytona/workspace/tb-presentation && ls /home/daytona/workspace/t…

Writing File

~/tb-presentation/create_tb_pptx.js

const pptxgen = require("pptxgenjs");

const pres = new pptxgen();
pres.layout = "LAYOUT_16x9";
pres.title = "Tuberculosis: Epidemiology & NTEP Strategies";
pres.author = "Medical Summary";

// ─── COLOR PALETTE ───────────────────────────────────────────────────────────
const C = {
  deepRed:   "8B1A1A",   // dominant dark red (TB awareness colour)
  midRed:    "C0392B",   // accent
  warmRed:   "E74C3C",   // highlight
  offWhite:  "FAF6F2",   // slide bg
  lightCream:"FDF3EF",
  cardBg:    "FFFFFF",
  textDark:  "2C1A1A",
  textMid:   "5D3A3A",
  textLight: "9B6B6B",
  accentGold:"D4A017",
  accentTeal:"1A7A8A",
  lightTeal: "E8F5F7",
  lightRed:  "FCE8E8",
};

// ─── HELPER FUNCTIONS ─────────────────────────────────────────────────────────
function addSlideHeader(slide, title, subtitle) {
  // Dark header bar at top
  slide.addShape(pres.shapes.RECTANGLE, {
    x: 0, y: 0, w: 10, h: 1.05,
    fill: { color: C.deepRed }, line: { color: C.deepRed }
  });
  // Red accent stripe
  slide.addShape(pres.shapes.RECTANGLE, {
    x: 0, y: 1.05, w: 10, h: 0.06,
    fill: { color: C.warmRed }, line: { color: C.warmRed }
  });
  slide.addText(title, {
    x: 0.35, y: 0.12, w: 8.8, h: 0.65,
    fontSize: 22, bold: true, color: "FFFFFF",
    fontFace: "Calibri", margin: 0
  });
  if (subtitle) {
    slide.addText(subtitle, {
      x: 0.35, y: 0.72, w: 8.8, h: 0.3,
      fontSize: 11, color: "F0C0C0",
      fontFace: "Calibri", margin: 0
    });
  }
}

function addSlideFooter(slide) {
  slide.addShape(pres.shapes.RECTANGLE, {
    x: 0, y: 5.45, w: 10, h: 0.175,
    fill: { color: C.deepRed }, line: { color: C.deepRed }
  });
  slide.addText("TB Epidemiology & NTEP  |  Summary Document", {
    x: 0.3, y: 5.455, w: 9.4, h: 0.16,
    fontSize: 7.5, color: "F5C5C5", fontFace: "Calibri",
    align: "center", margin: 0
  });
}

function addCard(slide, x, y, w, h, headerText, headerColor, items, headerFontSize, itemFontSize) {
  headerColor = headerColor || C.deepRed;
  headerFontSize = headerFontSize || 10.5;
  itemFontSize = itemFontSize || 9.5;

  slide.addShape(pres.shapes.RECTANGLE, {
    x, y, w, h,
    fill: { color: C.cardBg },
    line: { color: "E0D0D0", width: 1 },
    shadow: { type: "outer", color: "000000", blur: 4, offset: 2, angle: 135, opacity: 0.08 }
  });
  slide.addShape(pres.shapes.RECTANGLE, {
    x, y, w, h: 0.32,
    fill: { color: headerColor }, line: { color: headerColor }
  });
  slide.addText(headerText, {
    x: x + 0.1, y: y + 0.03, w: w - 0.15, h: 0.28,
    fontSize: headerFontSize, bold: true, color: "FFFFFF",
    fontFace: "Calibri", margin: 0
  });

  const textItems = items.map((item, i) => ({
    text: item,
    options: { bullet: { type: "bullet", characterCode: "25B8" }, breakLine: i < items.length - 1, fontSize: itemFontSize, color: C.textDark, fontFace: "Calibri" }
  }));
  slide.addText(textItems, {
    x: x + 0.12, y: y + 0.36, w: w - 0.22, h: h - 0.42,
    valign: "top"
  });
}

// ════════════════════════════════════════════════════════════════════════════
// SLIDE 1 — TITLE SLIDE
// ════════════════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  s.background = { color: C.deepRed };

  // Large white cross / TB ribbon visual block
  s.addShape(pres.shapes.RECTANGLE, {
    x: 0, y: 0, w: 10, h: 5.625,
    fill: { color: C.deepRed }, line: { color: C.deepRed }
  });
  // Decorative bottom band
  s.addShape(pres.shapes.RECTANGLE, {
    x: 0, y: 4.9, w: 10, h: 0.725,
    fill: { color: "6B1010" }, line: { color: "6B1010" }
  });
  // Gold accent line
  s.addShape(pres.shapes.RECTANGLE, {
    x: 0, y: 4.88, w: 10, h: 0.06,
    fill: { color: C.accentGold }, line: { color: C.accentGold }
  });
  // Left white sidebar
  s.addShape(pres.shapes.RECTANGLE, {
    x: 0, y: 0, w: 0.35, h: 5.625,
    fill: { color: "6B1010" }, line: { color: "6B1010" }
  });

  s.addText("TUBERCULOSIS", {
    x: 0.6, y: 0.8, w: 8.8, h: 0.9,
    fontSize: 44, bold: true, color: "FFFFFF",
    fontFace: "Calibri", charSpacing: 8, margin: 0
  });
  s.addText("Epidemiology, Prevention & NTEP Strategies", {
    x: 0.6, y: 1.72, w: 8.8, h: 0.55,
    fontSize: 18, color: "F5C0C0",
    fontFace: "Calibri", margin: 0
  });
  s.addShape(pres.shapes.RECTANGLE, {
    x: 0.6, y: 2.38, w: 3.5, h: 0.05,
    fill: { color: C.accentGold }, line: { color: C.accentGold }
  });
  s.addText([
    { text: "National Tuberculosis Elimination Programme (NTEP)", options: { breakLine: true } },
    { text: "India's Mission: TB Elimination by 2025", options: {} }
  ], {
    x: 0.6, y: 2.55, w: 8.5, h: 0.7,
    fontSize: 12.5, color: "FFDDCC", fontFace: "Calibri", margin: 0
  });
  s.addText([
    { text: "Source: ", options: { bold: true, breakLine: false } },
    { text: "Park's Textbook of Preventive & Social Medicine  |  Murray & Nadel's Respiratory Medicine  |  MoHFW India 2025", options: {} }
  ], {
    x: 0.6, y: 4.92, w: 9.2, h: 0.28,
    fontSize: 7.5, color: "F0C0C0", fontFace: "Calibri", margin: 0
  });
}

// ════════════════════════════════════════════════════════════════════════════
// SLIDE 2 — GLOBAL & INDIA BURDEN
// ════════════════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  s.background = { color: C.offWhite };
  addSlideHeader(s, "Global & Indian Burden of Tuberculosis", "Scale of the TB epidemic — worldwide and India's share");
  addSlideFooter(s);

  // Big stat boxes — row 1
  const stats = [
    { val: "1.7 Billion", label: "People infected\nglobally (latent TB)", color: C.deepRed },
    { val: "10 Million", label: "New TB cases\nper year (2018)", color: C.midRed },
    { val: "1.2 Million", label: "Deaths due to TB\nper year (2018)", color: "7B2020" },
    { val: "26%", label: "India's share of\nglobal TB cases", color: C.accentTeal },
  ];
  stats.forEach((st, i) => {
    const x = 0.25 + i * 2.42;
    s.addShape(pres.shapes.RECTANGLE, {
      x, y: 1.22, w: 2.25, h: 1.25,
      fill: { color: st.color }, line: { color: st.color },
      shadow: { type: "outer", color: "000000", blur: 5, offset: 2, angle: 135, opacity: 0.15 }
    });
    s.addText(st.val, {
      x: x + 0.05, y: 1.27, w: 2.15, h: 0.58,
      fontSize: 22, bold: true, color: "FFFFFF",
      fontFace: "Calibri", align: "center", margin: 0
    });
    s.addText(st.label, {
      x: x + 0.05, y: 1.85, w: 2.15, h: 0.55,
      fontSize: 9, color: "FFE0D0",
      fontFace: "Calibri", align: "center", margin: 0
    });
  });

  // India-specific data table
  s.addShape(pres.shapes.RECTANGLE, {
    x: 0.25, y: 2.6, w: 9.5, h: 0.3,
    fill: { color: C.deepRed }, line: { color: C.deepRed }
  });
  s.addText("INDIA — TB Burden 2019 (Population: 1,366 million)", {
    x: 0.35, y: 2.62, w: 9.2, h: 0.25,
    fontSize: 11, bold: true, color: "FFFFFF", fontFace: "Calibri", margin: 0
  });

  const tableData = [
    ["Parameter", "Number (thousands)", "Rate per 100,000"],
    ["Total Incidence", "2,640 (1,800–3,630)", "193 (132–266)"],
    ["HIV+TB Incidence", "71 (49–98)", "5.2 (3.6–7.2)"],
    ["MDR/RR-TB Incidence", "124 (73–189)", "9.1 (5.3–14)"],
    ["Mortality (HIV-negative)", "436 (404–469)", "32 (30–34)"],
    ["Mortality (HIV-positive)", "9.5 (6–14)", "0.69 (0.44–1)"],
  ];
  s.addTable(tableData, {
    x: 0.25, y: 2.9, w: 9.5, h: 2.25,
    fontSize: 9.5, fontFace: "Calibri",
    color: C.textDark,
    border: { type: "solid", color: "E0CACA", pt: 0.5 },
    fill: "FFFFFF",
    rowH: 0.35,
    colW: [3.2, 3.3, 3.0],
    align: "center",
    valign: "middle",
    autoPage: false,
  });
}

// ════════════════════════════════════════════════════════════════════════════
// SLIDE 3 — EPIDEMIOLOGICAL TRIAD (AGENT, HOST, ENVIRONMENT)
// ════════════════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  s.background = { color: C.offWhite };
  addSlideHeader(s, "Epidemiological Triad of Tuberculosis", "Agent, Host, and Environmental factors driving TB transmission");
  addSlideFooter(s);

  // Agent Card
  addCard(s, 0.2, 1.2, 3.1, 3.95, "AGENT — M. tuberculosis", C.deepRed, [
    "Acid-fast, aerobic, non-spore-forming bacillus",
    "7 phylogenetic lineages (Indo-Oceanic L1, East-Asian L2, Euro-American L4, etc.)",
    "Airborne droplet nuclei (1–5 microns)",
    "Source: Sputum of active pulmonary TB cases",
    "Survives hours in air; killed by UV light & heat",
    "1 smear+ve case infects 10–15 persons/year",
  ], 10.5, 9);

  // Host Card
  addCard(s, 3.45, 1.2, 3.1, 3.95, "HOST — Risk Factors", C.midRed, [
    "HIV (20–30x increased risk)",
    "Malnutrition & underweight",
    "Diabetes mellitus",
    "Age: <5 yrs, 15–30 yrs, elderly",
    "Tobacco & alcohol use",
    "Prior TB infection / fibrotic CXR lesions",
    "Immunosuppressive drugs (TNF-alpha inhibitors)",
  ], 10.5, 9);

  // Environment Card
  addCard(s, 6.7, 1.2, 3.1, 3.95, "ENVIRONMENT", C.accentTeal, [
    "Overcrowding (most important factor)",
    "Poor ventilation & low sunlight",
    "Urban slums & congregate settings",
    "Poverty & low socioeconomic status",
    "Prison & shelter populations",
    "Industrial exposure (silica dust)",
    "Indoor air pollution",
  ], 10.5, 9);

  // ARI note at bottom
  s.addShape(pres.shapes.RECTANGLE, {
    x: 0.2, y: 5.18, w: 9.6, h: 0.22,
    fill: { color: "FDF0E0" }, line: { color: C.accentGold }
  });
  s.addText("Annual Risk of Infection (ARI): 1% ARI = 50 new smear+ve cases/year per 100,000 population — best indicator of TB burden trend", {
    x: 0.28, y: 5.19, w: 9.44, h: 0.2,
    fontSize: 8.5, color: "5A3A00", fontFace: "Calibri", margin: 0, italic: true
  });
}

// ════════════════════════════════════════════════════════════════════════════
// SLIDE 4 — PREVENTION OF TB
// ════════════════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  s.background = { color: C.offWhite };
  addSlideHeader(s, "Prevention of Pulmonary Tuberculosis", "Two fundamental pillars: Case-finding + Treatment, and BCG Vaccination");
  addSlideFooter(s);

  // Pillar 1
  s.addShape(pres.shapes.RECTANGLE, {
    x: 0.2, y: 1.18, w: 4.7, h: 0.35,
    fill: { color: C.deepRed }, line: { color: C.deepRed }
  });
  s.addText("PILLAR 1 — Case-finding & Treatment (Most Powerful Weapon)", {
    x: 0.28, y: 1.2, w: 4.55, h: 0.3,
    fontSize: 10, bold: true, color: "FFFFFF", fontFace: "Calibri", margin: 0
  });
  const p1items = [
    { text: "Passive Case-finding: Symptomatic patients (>60%) self-present; persistent cough most common.", options: { bullet: true, breakLine: true, fontSize: 9, color: C.textDark, fontFace: "Calibri" } },
    { text: "Intensified Case-finding (ICF): Provider-initiated; targets vulnerable groups — PLHIV, contacts, homeless, prisoners.", options: { bullet: true, breakLine: true, fontSize: 9, color: C.textDark, fontFace: "Calibri" } },
    { text: "Screening tools: Symptom screening → Chest X-ray → Xpert MTB/RIF (CB-NAAT).", options: { bullet: true, breakLine: true, fontSize: 9, color: C.textDark, fontFace: "Calibri" } },
    { text: "TB Preventive Treatment (TPT): 6H / 3HP / 1HP regimens for household contacts, PLHIV, high-risk groups.", options: { bullet: true, fontSize: 9, color: C.textDark, fontFace: "Calibri" } },
  ];
  s.addShape(pres.shapes.RECTANGLE, {
    x: 0.2, y: 1.53, w: 4.7, h: 2.35,
    fill: { color: C.lightRed }, line: { color: "E0BABA" }
  });
  s.addText(p1items, { x: 0.3, y: 1.58, w: 4.5, h: 2.25, valign: "top" });

  // Pillar 2 — BCG
  s.addShape(pres.shapes.RECTANGLE, {
    x: 5.1, y: 1.18, w: 4.7, h: 0.35,
    fill: { color: C.accentTeal }, line: { color: C.accentTeal }
  });
  s.addText("PILLAR 2 — BCG Vaccination", {
    x: 5.18, y: 1.2, w: 4.55, h: 0.3,
    fontSize: 10, bold: true, color: "FFFFFF", fontFace: "Calibri", margin: 0
  });
  const p2items = [
    { text: "Efficacy: ~80% against severe childhood TB & TB meningitis; variable for adult pulmonary TB.", options: { bullet: true, breakLine: true, fontSize: 9, color: C.textDark, fontFace: "Calibri" } },
    { text: "India policy: Given at birth (institutional) or at 6 weeks (with DPT + OPV) intradermally, 0.1 mg/0.1 ml, above left deltoid.", options: { bullet: true, breakLine: true, fontSize: 9, color: C.textDark, fontFace: "Calibri" } },
    { text: "Reaction: Papule at 2–3 weeks → 4–8 mm scar by 6–12 weeks; Mantoux+ve in 8–14 weeks.", options: { bullet: true, breakLine: true, fontSize: 9, color: C.textDark, fontFace: "Calibri" } },
    { text: "Neonates: 0.05 ml dose to prevent local abscess from thinner skin.", options: { bullet: true, fontSize: 9, color: C.textDark, fontFace: "Calibri" } },
  ];
  s.addShape(pres.shapes.RECTANGLE, {
    x: 5.1, y: 1.53, w: 4.7, h: 2.35,
    fill: { color: C.lightTeal }, line: { color: "B0D8DE" }
  });
  s.addText(p2items, { x: 5.2, y: 1.58, w: 4.5, h: 2.25, valign: "top" });

  // Infection control section
  s.addShape(pres.shapes.RECTANGLE, {
    x: 0.2, y: 3.98, w: 9.6, h: 0.3,
    fill: { color: "6B1010" }, line: { color: "6B1010" }
  });
  s.addText("ADDITIONAL PREVENTION MEASURES — Infection Control & Social Determinants", {
    x: 0.3, y: 4.0, w: 9.3, h: 0.25,
    fontSize: 10, bold: true, color: "FFFFFF", fontFace: "Calibri", margin: 0
  });
  const addItems = [
    { text: "Admin: Rapid ID & isolation of infectious cases; cough etiquette; triage protocols.", options: { bullet: true, breakLine: true, fontSize: 9, color: C.textDark, fontFace: "Calibri" } },
    { text: "Environmental: Natural/mechanical ventilation; UV germicidal irradiation (UVGI) in health facilities.", options: { bullet: true, breakLine: true, fontSize: 9, color: C.textDark, fontFace: "Calibri" } },
    { text: "PPE: N95 respirators for HCWs in high-risk settings.", options: { bullet: true, breakLine: true, fontSize: 9, color: C.textDark, fontFace: "Calibri" } },
    { text: "Social determinants: Reduce overcrowding, poverty, malnutrition; multisectoral response; nutrition supplementation.", options: { bullet: true, fontSize: 9, color: C.textDark, fontFace: "Calibri" } },
  ];
  s.addShape(pres.shapes.RECTANGLE, {
    x: 0.2, y: 4.28, w: 9.6, h: 0.95,
    fill: { color: "FEF8F0" }, line: { color: "E8D8B0" }
  });
  s.addText(addItems, { x: 0.3, y: 4.3, w: 9.4, h: 0.9, valign: "top" });
}

// ════════════════════════════════════════════════════════════════════════════
// SLIDE 5 — NTEP OVERVIEW
// ════════════════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  s.background = { color: C.offWhite };
  addSlideHeader(s, "NTEP — National Tuberculosis Elimination Programme", "India's flagship TB programme under National Health Mission (NHM)");
  addSlideFooter(s);

  // Timeline bar
  const timeline = [
    { year: "1962", label: "NTP\nLaunched", color: C.textLight },
    { year: "1992", label: "RNTCP\nIntroduced", color: C.textMid },
    { year: "1997", label: "RNTCP\nNationwide", color: C.deepRed },
    { year: "2017", label: "NSP\n2017–25", color: C.midRed },
    { year: "2020", label: "RNTCP →\nNTEP", color: "C0392B" },
    { year: "2025", label: "TB Elimination\nTarget", color: C.accentGold },
  ];
  s.addShape(pres.shapes.RECTANGLE, {
    x: 0.2, y: 1.85, w: 9.6, h: 0.06,
    fill: { color: C.deepRed }, line: { color: C.deepRed }
  });
  timeline.forEach((t, i) => {
    const x = 0.3 + i * 1.58;
    s.addShape(pres.shapes.ELLIPSE, {
      x: x + 0.45, y: 1.68, w: 0.22, h: 0.22,
      fill: { color: t.color }, line: { color: "FFFFFF", width: 1.5 }
    });
    s.addText(t.year, {
      x: x + 0.2, y: 1.35, w: 0.7, h: 0.28,
      fontSize: 10, bold: true, color: t.color,
      fontFace: "Calibri", align: "center", margin: 0
    });
    s.addText(t.label, {
      x: x + 0.1, y: 2.0, w: 0.9, h: 0.42,
      fontSize: 7.5, color: C.textMid,
      fontFace: "Calibri", align: "center", margin: 0
    });
  });

  // Objectives + Vision
  s.addShape(pres.shapes.RECTANGLE, {
    x: 0.2, y: 2.6, w: 4.65, h: 0.3,
    fill: { color: C.deepRed }, line: { color: C.deepRed }
  });
  s.addText("OBJECTIVES", {
    x: 0.3, y: 2.62, w: 4.45, h: 0.25,
    fontSize: 10.5, bold: true, color: "FFFFFF", fontFace: "Calibri", margin: 0
  });
  s.addShape(pres.shapes.RECTANGLE, {
    x: 0.2, y: 2.9, w: 4.65, h: 2.35,
    fill: { color: C.lightRed }, line: { color: "E0BABA" }
  });
  s.addText([
    { text: "Eliminate TB in India by 2025 (<1 case/million population)", options: { bullet: true, breakLine: true, fontSize: 9, color: C.textDark, fontFace: "Calibri" } },
    { text: "Reduce TB incidence by 90% and mortality by 95% (vs. 2015 baseline)", options: { bullet: true, breakLine: true, fontSize: 9, color: C.textDark, fontFace: "Calibri" } },
    { text: "Zero TB-affected families face catastrophic costs", options: { bullet: true, breakLine: true, fontSize: 9, color: C.textDark, fontFace: "Calibri" } },
    { text: "Universal access to quality TB care (public + private)", options: { bullet: true, breakLine: true, fontSize: 9, color: C.textDark, fontFace: "Calibri" } },
    { text: "SDG 3: End TB Epidemic by 2030 (India targets 5 years ahead)", options: { bullet: true, fontSize: 9, color: C.textDark, fontFace: "Calibri" } },
  ], { x: 0.3, y: 2.95, w: 4.45, h: 2.25, valign: "top" });

  // Four pillars
  s.addShape(pres.shapes.RECTANGLE, {
    x: 5.1, y: 2.6, w: 4.7, h: 0.3,
    fill: { color: C.accentTeal }, line: { color: C.accentTeal }
  });
  s.addText("NSP FOUR PILLARS", {
    x: 5.2, y: 2.62, w: 4.5, h: 0.25,
    fontSize: 10.5, bold: true, color: "FFFFFF", fontFace: "Calibri", margin: 0
  });

  const pillars = [
    { icon: "D", label: "DETECT", sub: "Xpert/CB-NAAT, UDST, ICF", color: C.deepRed },
    { icon: "T", label: "TREAT", sub: "Daily regimens, DR-TB mgmt", color: C.midRed },
    { icon: "P", label: "PREVENT", sub: "BCG, TPT, infection control", color: C.accentTeal },
    { icon: "B", label: "BUILD", sub: "Nikshay, private sector, NHM", color: "7B5A00" },
  ];
  pillars.forEach((p, i) => {
    const px = 5.15 + i * 1.17;
    s.addShape(pres.shapes.RECTANGLE, {
      x: px, y: 3.0, w: 1.1, h: 2.2,
      fill: { color: p.color }, line: { color: p.color },
      shadow: { type: "outer", color: "000000", blur: 4, offset: 2, angle: 135, opacity: 0.12 }
    });
    s.addText(p.label, {
      x: px + 0.02, y: 3.05, w: 1.06, h: 0.42,
      fontSize: 13, bold: true, color: "FFFFFF",
      fontFace: "Calibri", align: "center", margin: 0
    });
    s.addText(p.sub, {
      x: px + 0.04, y: 3.55, w: 1.02, h: 1.55,
      fontSize: 8.5, color: "FFEECC",
      fontFace: "Calibri", align: "center", wrap: true, valign: "top"
    });
  });
}

// ════════════════════════════════════════════════════════════════════════════
// SLIDE 6 — KEY STRATEGIES OF NTEP
// ════════════════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  s.background = { color: C.offWhite };
  addSlideHeader(s, "NTEP — Key Strategies", "Core operational strategies driving TB elimination in India");
  addSlideFooter(s);

  const strategies = [
    {
      title: "DOTS", color: C.deepRed,
      items: ["Directly Observed Treatment Short-course", "Cornerstone of RNTCP/NTEP", "Ensures treatment adherence", "Free drugs at DOT centres"],
    },
    {
      title: "Universal DST (UDST)", color: C.midRed,
      items: ["All newly diagnosed TB patients tested upfront for drug resistance", "CB-NAAT / Xpert MTB/RIF: 90-min result", "Line Probe Assay (LPA): 1st & 2nd line", "Guides appropriate regimen choice"],
    },
    {
      title: "Daily Drug Regimens", color: "7B2020",
      items: ["Shift from thrice-weekly to daily dosing", "Reduces risk of acquired drug resistance", "Better pharmacokinetics & outcomes", "Applied across all TB categories"],
    },
    {
      title: "Private Sector Engagement", color: C.accentTeal,
      items: ["Mandatory TB notification by private providers", "Nikshay platform for notifications", "Incentives for private labs & providers", ">50% TB burden in private sector"],
    },
    {
      title: "DR-TB Management", color: "1A5A6A",
      items: ["Dedicated DRTB centres nationwide", "Shorter MDR-TB regimens (9-month)", "BPaLM regimen (Bedaquiline, Pretomanid,  Linezolid, Moxifloxacin)", "Delamanid for XDR-TB"],
    },
    {
      title: "Multisectoral Response", color: "5A7A00",
      items: ["24 line ministries involved", "Nutrition, housing, education links", "Social protection for TB patients", "Whole-of-government approach"],
    },
  ];

  strategies.forEach((st, i) => {
    const col = i % 3;
    const row = Math.floor(i / 3);
    addCard(s, 0.2 + col * 3.25, 1.22 + row * 2.12, 3.1, 2.0, st.title, st.color, st.items, 10, 8.5);
  });
}

// ════════════════════════════════════════════════════════════════════════════
// SLIDE 7 — NEWER INITIATIVES
// ════════════════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  s.background = { color: C.offWhite };
  addSlideHeader(s, "NTEP — Newer Initiatives (2018–2025)", "Recent programme innovations accelerating TB elimination in India");
  addSlideFooter(s);

  const initiatives = [
    {
      year: "2012", name: "Nikshay Platform",
      desc: "Web-based TB case notification & patient tracking system. Real-time monitoring of treatment outcomes. Used by public & private providers.",
      color: C.textMid,
    },
    {
      year: "2018", name: "Nikshay Poshan Yojana",
      desc: "Direct benefit transfer of Rs. 500/month to all TB patients for nutritional support during treatment — countering drug side effects & malnutrition.",
      color: C.midRed,
    },
    {
      year: "2022 Sep", name: "PM TB Mukt Bharat Abhiyaan",
      desc: "Jan Andolan (people's movement) to unite all sections of society. Objectives: Additional patient support, community engagement, leverage CSR funds.",
      color: C.deepRed,
    },
    {
      year: "2022", name: "Ni-kshay Mitra Programme",
      desc: "Volunteer 'friends of TB patients' — individuals, NGOs, corporates — provide nutritional, diagnostic & vocational support beyond government facilities.",
      color: "7B2020",
    },
    {
      year: "2024 Dec", name: "100-Day TB Mukt Bharat Abhiyan",
      desc: "Intensive drive in 347 high-priority districts across 33 States/UTs. Vulnerability mapping, systematic screening, 30,000+ elected reps, 24 ministries involved. Now expanded nationwide.",
      color: "C0392B",
    },
    {
      year: "Ongoing", name: "New Drug Regimens",
      desc: "BPaLM for MDR-TB; shorter 6-9 month regimens; Bedaquiline & Delamanid conditional access. UDST enabling precision treatment for all TB patients.",
      color: C.accentTeal,
    },
  ];

  initiatives.forEach((init, i) => {
    const col = i % 2;
    const row = Math.floor(i / 2);
    const x = 0.2 + col * 4.88;
    const y = 1.22 + row * 1.47;

    s.addShape(pres.shapes.RECTANGLE, {
      x, y, w: 4.7, h: 1.38,
      fill: { color: C.cardBg },
      line: { color: "E0D0D0", width: 0.75 },
      shadow: { type: "outer", color: "000000", blur: 3, offset: 1.5, angle: 135, opacity: 0.07 }
    });
    // Year badge
    s.addShape(pres.shapes.RECTANGLE, {
      x, y, w: 1.0, h: 0.3,
      fill: { color: init.color }, line: { color: init.color }
    });
    s.addText(init.year, {
      x: x + 0.03, y: y + 0.04, w: 0.94, h: 0.22,
      fontSize: 8.5, bold: true, color: "FFFFFF", fontFace: "Calibri",
      align: "center", margin: 0
    });
    // Initiative name
    s.addText(init.name, {
      x: x + 1.05, y: y + 0.04, w: 3.55, h: 0.25,
      fontSize: 10.5, bold: true, color: init.color,
      fontFace: "Calibri", margin: 0
    });
    // Description
    s.addText(init.desc, {
      x: x + 0.12, y: y + 0.34, w: 4.46, h: 0.98,
      fontSize: 8.5, color: C.textDark, fontFace: "Calibri",
      valign: "top", wrap: true
    });
  });
}

// ════════════════════════════════════════════════════════════════════════════
// SLIDE 8 — NTEP STRUCTURE & AGE / SEX DISTRIBUTION
// ════════════════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  s.background = { color: C.offWhite };
  addSlideHeader(s, "NTEP Programme Structure & India TB Profile", "Organizational hierarchy and demographic distribution of TB cases");
  addSlideFooter(s);

  // Structure
  s.addShape(pres.shapes.RECTANGLE, {
    x: 0.2, y: 1.22, w: 5.0, h: 0.3,
    fill: { color: C.deepRed }, line: { color: C.deepRed }
  });
  s.addText("NTEP ORGANISATIONAL STRUCTURE", {
    x: 0.3, y: 1.24, w: 4.8, h: 0.25,
    fontSize: 10.5, bold: true, color: "FFFFFF", fontFace: "Calibri", margin: 0
  });

  const levels = [
    { name: "Central TB Division (CTD)", level: "National", color: C.deepRed, w: 3.8 },
    { name: "State TB Cell (STC)", level: "State", color: C.midRed, w: 3.4 },
    { name: "District TB Centre (DTC)", level: "District", color: "B03030", w: 2.9 },
    { name: "TB Unit (TU)", level: "Sub-district", color: "8B2020", w: 2.5 },
    { name: "DOT Centre / Microscopy Centre (DMC)", level: "Peripheral", color: "6B1515", w: 4.2 },
    { name: "DRTB Centres", level: "Specialized", color: C.accentTeal, w: 2.4 },
  ];

  levels.forEach((lv, i) => {
    const lx = 0.3 + (5.0 - lv.w) / 2;
    const ly = 1.6 + i * 0.55;
    s.addShape(pres.shapes.ROUNDED_RECTANGLE, {
      x: lx, y: ly, w: lv.w, h: 0.38,
      fill: { color: lv.color }, line: { color: lv.color }, rectRadius: 0.05
    });
    s.addText(`${lv.name}  |  ${lv.level}`, {
      x: lx + 0.08, y: ly + 0.06, w: lv.w - 0.12, h: 0.26,
      fontSize: 9, bold: true, color: "FFFFFF",
      fontFace: "Calibri", align: "center", margin: 0
    });
    if (i < levels.length - 1) {
      const arrowX = 0.3 + (5.0 - 0.15) / 2;
      s.addShape(pres.shapes.RECTANGLE, {
        x: arrowX, y: ly + 0.38, w: 0.15, h: 0.17,
        fill: { color: "CCAAAA" }, line: { color: "CCAAAA" }
      });
    }
  });

  // Age & key stats panel
  s.addShape(pres.shapes.RECTANGLE, {
    x: 5.45, y: 1.22, w: 4.35, h: 0.3,
    fill: { color: C.accentTeal }, line: { color: C.accentTeal }
  });
  s.addText("KEY INDIA TB PROFILE", {
    x: 5.55, y: 1.24, w: 4.15, h: 0.25,
    fontSize: 10.5, bold: true, color: "FFFFFF", fontFace: "Calibri", margin: 0
  });
  s.addShape(pres.shapes.RECTANGLE, {
    x: 5.45, y: 1.52, w: 4.35, h: 3.73,
    fill: { color: C.lightTeal }, line: { color: "B0D8DE" }
  });
  s.addText([
    { text: "Age Distribution", options: { bold: true, breakLine: true, fontSize: 10.5, color: C.accentTeal, fontFace: "Calibri" } },
    { text: "15–30 years: Dominant age group (active transmission)", options: { bullet: true, breakLine: true, fontSize: 9, color: C.textDark, fontFace: "Calibri" } },
    { text: "Southern states (KL, KA, TN, AP): Shift to 50+ year group", options: { bullet: true, breakLine: true, fontSize: 9, color: C.textDark, fontFace: "Calibri" } },
    { text: "\n", options: { fontSize: 5, breakLine: true } },
    { text: "Case Distribution", options: { bold: true, breakLine: true, fontSize: 10.5, color: C.accentTeal, fontFace: "Calibri" } },
    { text: "78% of notified cases: Pulmonary TB", options: { bullet: true, breakLine: true, fontSize: 9, color: C.textDark, fontFace: "Calibri" } },
    { text: "22% of notified cases: Extra-pulmonary TB", options: { bullet: true, breakLine: true, fontSize: 9, color: C.textDark, fontFace: "Calibri" } },
    { text: "80% of notified cases: Known HIV status", options: { bullet: true, breakLine: true, fontSize: 9, color: C.textDark, fontFace: "Calibri" } },
    { text: "17% tested with rapid diagnostics at diagnosis", options: { bullet: true, breakLine: true, fontSize: 9, color: C.textDark, fontFace: "Calibri" } },
    { text: "\n", options: { fontSize: 5, breakLine: true } },
    { text: "Drug Resistance", options: { bold: true, breakLine: true, fontSize: 10.5, color: C.deepRed, fontFace: "Calibri" } },
    { text: "New cases: 2.8% MDR/RR-TB", options: { bullet: true, breakLine: true, fontSize: 9, color: C.textDark, fontFace: "Calibri" } },
    { text: "Previously treated: 14% MDR/RR-TB", options: { bullet: true, breakLine: true, fontSize: 9, color: C.textDark, fontFace: "Calibri" } },
    { text: "Treatment Coverage: 82% (2019)", options: { bullet: true, fontSize: 9, color: C.textDark, fontFace: "Calibri" } },
  ], { x: 5.55, y: 1.57, w: 4.15, h: 3.63, valign: "top" });
}

// ════════════════════════════════════════════════════════════════════════════
// SLIDE 9 — END SLIDE
// ════════════════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  s.background = { color: C.deepRed };

  s.addShape(pres.shapes.RECTANGLE, {
    x: 0, y: 0, w: 10, h: 5.625,
    fill: { color: C.deepRed }, line: { color: C.deepRed }
  });
  s.addShape(pres.shapes.RECTANGLE, {
    x: 0, y: 4.5, w: 10, h: 1.125,
    fill: { color: "6B1010" }, line: { color: "6B1010" }
  });
  s.addShape(pres.shapes.RECTANGLE, {
    x: 0, y: 4.48, w: 10, h: 0.05,
    fill: { color: C.accentGold }, line: { color: C.accentGold }
  });

  s.addText("TB MUKT BHARAT", {
    x: 0.5, y: 0.8, w: 9, h: 1.0,
    fontSize: 46, bold: true, color: "FFFFFF",
    fontFace: "Calibri", charSpacing: 6, align: "center", margin: 0
  });
  s.addText("TB-Free India by 2025", {
    x: 0.5, y: 1.88, w: 9, h: 0.55,
    fontSize: 20, color: "FFD0C0",
    fontFace: "Calibri", align: "center", margin: 0
  });
  s.addShape(pres.shapes.RECTANGLE, {
    x: 3.2, y: 2.55, w: 3.6, h: 0.05,
    fill: { color: C.accentGold }, line: { color: C.accentGold }
  });
  s.addText([
    { text: "Detect  |  Treat  |  Prevent  |  Build", options: { bold: true, breakLine: true } },
    { text: "NTEP — National Strategic Plan 2017–2025", options: {} },
  ], {
    x: 0.5, y: 2.75, w: 9, h: 0.7,
    fontSize: 13, color: "F5C5C5", fontFace: "Calibri", align: "center", margin: 0
  });

  s.addText([
    { text: "Sources: ", options: { bold: true } },
    { text: "Park's Textbook of Preventive & Social Medicine (24e)  •  Murray & Nadel's Respiratory Medicine  •  MoHFW / PIB India 2025", options: {} }
  ], {
    x: 0.5, y: 4.54, w: 9, h: 0.5,
    fontSize: 8, color: "F0C0C0", fontFace: "Calibri", align: "center", margin: 0
  });
}

// ── WRITE FILE ──────────────────────────────────────────────────────────────
pres.writeFile({ fileName: "/home/daytona/workspace/tb-presentation/TB_Epidemiology_NTEP.pptx" })
  .then(() => console.log("SUCCESS: File written."))
  .catch(err => { console.error("ERROR:", err); process.exit(1); });
Running Command

cd /home/daytona/workspace/tb-presentation && node create_tb_pptx.js

Running Command

node -e "const p = require('pptxgenjs'); const pr = new p(); console.log(Object.…

Editing File

~/tb-presentation/create_tb_pptx.js

Successfully replaced 1 instance(s) of the string in '/home/daytona/workspace/tb-presentation/create_tb_pptx.js'
Running Command

cd /home/daytona/workspace/tb-presentation && node create_tb_pptx.js

Running Command

ls -lh /home/daytona/workspace/tb-presentation/TB_Epidemiology_NTEP.pptx

Your PowerPoint presentation is ready (279 KB, 9 slides):

TB Epidemiology NTEP

Presentation · PPTX


Slide-by-slide contents:
#SlideContent
1Title"Tuberculosis: Epidemiology, Prevention & NTEP Strategies" with programme tagline
2Global & India Burden4 stat boxes (1.7B infected, 10M new cases, 1.2M deaths, India 26%) + India 2019 data table
3Epidemiological Triad3 cards - Agent (M. tuberculosis), Host risk factors, Environmental factors + ARI note
4PreventionPillar 1 (Case-finding & Treatment, ICF, TPT) + Pillar 2 (BCG vaccination, dosage, reactions) + Infection control measures
5NTEP OverviewHistorical timeline (1962→2025) + Objectives + NSP 4 Pillars (Detect/Treat/Prevent/Build)
6Key Strategies6 strategy cards: DOTS, UDST, Daily regimens, Private sector engagement, DR-TB management, Multisectoral response
7Newer Initiatives6 initiative cards with year badges: Nikshay (2012), Nikshay Poshan Yojana (2018), PM TB Mukt Bharat Abhiyaan (2022), Ni-kshay Mitra (2022), 100-Day Abhiyan (Dec 2024), New drug regimens
8Structure & ProfileNTEP organisational hierarchy + India TB demographic profile (age distribution, case split, MDR rates)
9End slide"TB Mukt Bharat" closing with 4-pillar tagline
The design uses a deep red palette (consistent with global TB awareness branding), data tables, info cards, and a timeline - all sourced from Park's Textbook, Murray & Nadel, and MoHFW India 2025.
This is a shared conversation. Sign in to Orris to start your own chat.